Next Article in Journal
Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells
Previous Article in Journal
Clostridium Bacteria and Autism Spectrum Conditions: A Systematic Review and Hypothetical Contribution of Environmental Glyphosate Levels
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
Med. Sci. 2018, 6(2), 30; https://doi.org/10.3390/medsci6020030

Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients

1
Joe DiMaggio Children’s Hospital Heart Institute, Memorial Health Care, Hollywood, FL 33021, USA
2
Children’s Health Heart Institute, Dallas, Texas 75235, USA
3
Department of Pediatrics, UTSW Medical Center, Dallas, Texas 75235, USA
*
Author to whom correspondence should be addressed.
Received: 21 February 2018 / Revised: 26 March 2018 / Accepted: 3 April 2018 / Published: 8 April 2018
(This article belongs to the Section Immunology and Infectious Diseases)
Full-Text   |   PDF [11301 KB, uploaded 3 May 2018]   |  

Abstract

Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients. View Full-Text
Keywords: cimetidine; cutaneous warts; pediatric heart transplant recipients cimetidine; cutaneous warts; pediatric heart transplant recipients
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Das, B.B.; Anton, K.; Soares, N.; Riojas, S.; Mcdermott, J.; Knox, L.; Daneman, S.; Puente, B.N. Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients. Med. Sci. 2018, 6, 30.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top